Business Wire

Market Survey by TSUNO Group Reveals “Rice Bran Oil” Market in Japan Is Expanding Under COVID-19 Pandemic

Share

TSUNO Group (HQ: Wakayama, Japan https://www.tsuno.co.jp) surveys the sales figure of edible vegetable oils and rice bran oil in Japan. (Data of The Nikkei 64 major chains stores and 461 stores in Japan March to May result based on total sales).
As a result, the market of Rice Bran Oil for household use has expanded by 42% compared to the previous year.
While the vegetable oil sales increased by 11% from previous year, rice bran oil and sesame oil sales grew by 42% during a state of emergency in Japan.
The rapid expansion of these two oils could be explained by a rise in people’s health-consciousness under COVID-19 pandemic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005397/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

TSUNO brand rice bran oils sized from 180g to 1500g. Full nutrients from rice bran are contained. Rice Bran Oil has strong anti oxidant effect and its healthy and goes well with any kind of dishes from dressing to deep fries. (Photo: Business Wire)

[Insights]
The growth of edible vegetable oil market for household use due to the increase in the number of people staying at home.
After the declaration of state of emergency from the Government of Japan, , the number of people who cook at home increased from various reasons : work from home, closure of schools and restaurants.
The rise in demand for edible vegetable oils is one of the key points to consider the rapid expansion of rice bran oil market.

The rise in demand for healthy and versatile vegetable oils.
Rice bran oil and sesame oil are highly versatile for daily use. The demand for rice bran oil has expanded because it’s resistant to oxidation and Japanese people could have a good impression on its healthy aspect.

Sales of TSUNO bran rice bran oil expanded.
The TSUNO brand rice bran oil ranges from 180g to 1500g.
Usually, 500g size is the most popular however 1500g sales has increased in this pandemic period.
Rice bran oil is recognized as a healthy oil that can be used any kind of dishes in daily use.
A survey conducted in 2019 for TSUNO’s EC site members in Japan shows that rice bran oil is used in fried foods, stir-fried foods, simmered foods, and dressings including Japanese-style Chinese and western style foods.

About TSUNO Group Co., Ltd.

TSUNO Group aims at contributing to health, beauty and environment protection through investigation of rice bran.
We operate three business, all of them are utilizing Rice bran that is generated from rice, one of the world’s three major grains.
Our products are used by wide range of customers, from general household, food industry, medical industry to cosmetic industry.
We have businesses with approximately 40 countries all over the world.
Since its foundation, TSUNO group has been prioritized quality control, environment and safety as the basis of all corporate activities, including research and development, production, distribution and sales.
Believing “environmentally friendly products bring people’s beauty and health”, we proactively continue and keep on improving our sustainable corporate activities.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mai Sakaue
TSUNO Group Co., Ltd.
+81-80-4245-7991
pr@tsuno.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release

SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho

Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 19:07:00 EET | Press release

CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundreds of industrial AI experts and leading hardware and software. “Together, we are building the Industrial AI operating system – redefining how the physical world is designed, built, and run - to scale AI and create real-world impact,” said Roland Busch, President and CEO of Siemens AG. “By combining NVIDIA’s leadership in accelerated computing and AI platforms with Siemens’ leading hardware, software, industrial AI and data, we’re empowering customers to develop products faster with the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye